{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:06:05Z","timestamp":1782936365464,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection that predominantly affects immunocompromised individuals, most commonly HIV-infected patients with significantly reduced CD4+lymphocyte counts, and is associated with high clinical mortality. Currently, there are few reports of pneumothorax secondary to PJP, and most cases occur in HIV-infected populations. However, PJP complicated by hydropneumothorax in cancer patients receiving immunotherapy is exceedingly rare, with limited reports in the literature. To our knowledge, this article reports a rare clinical case of Pneumocystis jirovecii infection complicated by left-sided hydropneumothorax in a patient with stage IVB clear cell renal cell carcinoma after immunotherapy, aiming to provide valuable insights for the early diagnosis and management of PJP and its complications in cancer patients undergoing immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 57-year-old male patient had previously undergone surgical treatment for left renal clear cell carcinoma, and developed recurrent metastases to the descending colon, liver, and upper pole of the left kidney after surgery, with a clinical stage of T4NxM1 stage IVB. After receiving targeted combination immunotherapy with sequential PD-1 inhibitors (toripalimab) plus anti-angiogenic agents (sunitinib, axitinib)\u2014a regimen that enhances anti-tumor immunity but may disrupt pulmonary immune homeostasis\u2014the patient gradually developed progressive dyspnea, chest tightness, hypoxemia, and anuria. Multiple auxiliary examinations were performed clinically, including chest X-ray, bronchoalveolar lavage, and metagenomic sequencing of pathogenic microorganisms. Based on the above examination results, the final diagnosis was Pneumocystis jirovecii pneumonia complicated by left-sided hydropneumothorax.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although PJP complicated by hydropneumothorax after immunotherapy is rare, it should be considered as a possible etiology when cancer patients develop progressive dyspnea with difficulty maintaining oxygen saturation after receiving immune checkpoint inhibitor-based therapy, particularly in the context of immune checkpoint inhibitor use. While biomarkers for predicting immunotherapy efficacy and irAEs are well-studied, the identification of specific biomarkers for predicting opportunistic infections like PJP in this context remains an area of active research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1784855","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:26:51Z","timestamp":1774268811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A rare case of Pneumocystis jirovecii infection with left hydropneumothorax following immunotherapy for stage IVB clear cell renal cell carcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Li","family":"Jiang","sequence":"first","affiliation":[{"name":"Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ye","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Cai","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"He","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine","place":["Guiyang, Guizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1378\/chest.108.4.946","article-title":"AIDS-related spontaneous pneumothorax. Risk factors and treatment","volume":"108","author":"Metersky","year":"1995","journal-title":"Chest"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"113710","DOI":"10.1016\/j.isci.2025.113710","article-title":"Pneumocystis jirovecii associated with lung Virome in patients with severe pneumonia","volume":"28","author":"Huang","year":"2025","journal-title":"iScience"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1521641","DOI":"10.3389\/fcimb.2025.1521641","article-title":"The impact of bronchoalveolar lavage fluid metagenomics next-generation sequencing on the diagnosis and management of patients with suspected pulmonary infection","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijid.2016.03.018","article-title":"Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients","volume":"46","author":"Bienvenu","year":"2016","journal-title":"Int J Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12890-024-03093-8","article-title":"A combined immune and inflammatory indicator predict the prognosis of severe pneumocystis jirovecii pneumonia patients: a 12-year, retrospective, observational cohort","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"830631","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"769124","DOI":"10.3389\/fonc.2022.769124","article-title":"Research progress of anti-PD-1\/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC","volume":"12","author":"Bie","year":"2022","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"17626","DOI":"10.1038\/s41598-020-72711-2","article-title":"Baseline IFN-\u03b3 and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients","volume":"10","author":"Giunta","year":"2020","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.ccell.2024.05.016","article-title":"Breaking up the CD8+ T cell: Treg pas de deux","volume":"42","author":"Zhang","year":"2024","journal-title":"Cancer Cell"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1165\/rcmb.2019-0234OC","article-title":"PD-1 deficiency promotes macrophage activation and T-helper cell type 1\/T-helper cell type 17 response in pneumocystis pneumonia","volume":"62","author":"Zhang","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/CM9.0000000000000237","article-title":"Programmed death ligand 1 is overexpressed by neutrophils in the blood of immunocompromised human immunodeficiency virus-negative patients with pneumocystis jirovecii pneumonia","volume":"132","author":"Zhang","year":"2019","journal-title":"Chin Med J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.2169\/internalmedicine.1163-22","article-title":"Pneumocystis pneumonia infection following the initiation of Pembrolizumab therapy for lung adenocarcinoma","volume":"62","author":"Sumi","year":"2023","journal-title":"Intern Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.chest.2024.07.140","article-title":"Clinical characteristics and prognosis of patients with severe pneumonia with pneumocystis jirovecii colonization: a multicenter, retrospective study","volume":"167","author":"Jiang","year":"2025","journal-title":"Chest"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41598-019-38618-3","article-title":"Risk factors and clinical characteristics of pneumocystis jirovecii pneumonia in lung cancer","volume":"9","author":"Lee","year":"2019","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/s12887-025-06288-y","article-title":"Clinical analysis of pneumocystis jirovecii pneumonia in children with malignant disease","volume":"25","author":"Luo","year":"2025","journal-title":"BMC Pediatr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12281-024-00482-8","article-title":"Pneumocystis jirovecii pneumonia in HIV-negative, non-transplant patients: epidemiology, clinical manifestations, diagnosis, treatment, and prevention","volume":"18","author":"Rhoads","year":"2024","journal-title":"Curr Fungal Infect Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e0156325","DOI":"10.1128\/spectrum.01563-25","article-title":"Real-time polymerase chain reaction (PCR) for pneumocystis jirovecii detection in lower respiratory tract samples","volume":"13","author":"Giardina","year":"2025","journal-title":"Microbiol Spectrum"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12890-024-03135-1","article-title":"Metagenomic next-generation sequencing promotes diagnosis and treatment of pneumocystis jirovecii pneumonia in non-HIV infected children: a retrospective study","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.2147\/IDR.S459722","article-title":"Metagenomic next-generation sequencing for accurate diagnosis of pneumocystis jirovecii pneumonia: a comparative study with traditional methods","volume":"17","author":"Luo","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"116168","DOI":"10.1016\/j.diagmicrobio.2023.116168","article-title":"Clinical performance of BALF droplet digital PCR for differential diagnosis of pneumocystis jirovecii pneumonia and pneumocystis jirovecii colonization","volume":"108","author":"Bian","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3201\/eid1903.121151","article-title":"Increasing pneumocystis pneumonia, England, UK, 2000-2010","volume":"19","author":"Maini","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12967-025-06332-6","article-title":"Impact of metagenomics next-generation sequencing on etiological diagnosis and early outcomes in sepsis","volume":"23","author":"Xu","year":"2025","journal-title":"J Transl Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1378\/chest.100.5.1224","article-title":"Pneumothorax with pneumocystis carinii pneumonia in AIDS. Incidence and clinical characteristics","volume":"100","author":"McClellan","year":"1991","journal-title":"Chest"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000487713","article-title":"Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with pneumocystis jirovecii pneumonia","volume":"96","author":"Salzer","year":"2018","journal-title":"Respiration"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.cmi.2024.12.024","article-title":"Comparative efficacy and safety of treatment regimens for pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials","volume":"31","author":"Hatzl","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/S2213-2600(25)00125-0","article-title":"Adjunctive corticosteroids in non-AIDS patients with severe pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial","volume":"13","author":"Lemiale","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis against Pneumocystis jirovecii pneumonia in adults","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s00134-024-07489-2","article-title":"Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study","volume":"50","author":"Kamel","year":"2024","journal-title":"Intensive Care Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01644","article-title":"Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer","author":"Raimondi","year":"2020","journal-title":"Front Oncol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","article-title":"Current status of immune checkpoint inhibitors for gastric cancer","volume":"23","author":"Kono","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"ref36","first-page":"338","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume-title":"Cell Commun Signal","author":"Yang","year":"2024"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1007\/s00520-020-05478-x","article-title":"Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy","volume":"28","author":"Jiang","year":"2020","journal-title":"Support Care Cancer"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"109204","DOI":"10.1016\/j.clim.2022.109204","article-title":"Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1\/PD-L1 immunotherapy","volume":"246","author":"Mei","year":"2023","journal-title":"Clin Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1111\/1759-7714.13703","article-title":"Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer","volume":"11","author":"Moda","year":"2020","journal-title":"Thorac Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.3390\/cancers12082314","article-title":"Endocrine adverse events of Nivolumab in non-small cell lung Cancer patients-literature review","volume":"12","author":"Dudzi\u0144ska","year":"2020","journal-title":"Cancers"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e000472","DOI":"10.1136\/esmoopen-2018-000472","article-title":"Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events","volume":"4","author":"Hoefsmit","year":"2019","journal-title":"ESMO Open"}],"updated-by":[{"DOI":"10.3389\/fmed.2026.1838047","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1784855\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:20:16Z","timestamp":1782930016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1784855\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":43,"alternative-id":["10.3389\/fmed.2026.1784855"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1784855","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"1784855"}}